Jpmorgan Chase & CO Unicycive Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 207 shares of UNCY stock, worth $134. This represents 0.0% of its overall portfolio holdings.
Number of Shares
207
Previous 70
195.71%
Holding current value
$134
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding UNCY
# of Institutions
31Shares Held
46.8MCall Options Held
0Put Options Held
0-
Great Point Partners LLC Greenwich, CT8.56MShares$5.56 Million1.62% of portfolio
-
Octagon Capital Advisors LP New York, NY8.56MShares$5.56 Million0.85% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$3.3 Million0.28% of portfolio
-
Walleye Capital LLC Plymouth, MN5MShares$3.25 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.47MShares$2.91 Million0.27% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $9.78M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...